Disease burden of prostate cancer from 2014 to 2019 in the United States: estimation from the Global Burden of Disease Study 2019 and Medical Expenditure Panel Survey

• DOI: 10.4178/epih.e2023038
• Publication Date: 2023-03-22T01:33:07Z
• Authors: Shen Lin; Dong Lin; Yiyuan Li; Lixian Zhong; Wei Zhou; Yajing Wu; Chen Xie; Shaohong Luo; Xiaoting Huang; Xiongwei Xu; Xiuhua Weng
• Keywords: Adult; Aged, 80 and over; Male; Adolescent; R; Prostatic Neoplasms; Comorbidity; Middle Aged; prostate cancer; United States; healthcare costs; disease burden; Young Adult; Cost of Illness; global burden of disease study; Medicine; Humans; Original Article; Health Expenditures; medical expenditure panel survey; Aged

The aim of this study was to evaluate the disease burden prostate cancer (PC) and assess key influencing factors associated with expenditures PC in United States.The total deaths, incidence, prevalence, disability-adjusted life-years were obtained from Global Burden Disease Study 2019. Medical Expenditure Panel Survey used estimate healthcare productivity loss investigate patterns payment use resources States. A multivariable logistic regression model conducted identify expenditures.For patients aged 50 older, for all age groups showed a modest increase over 6-year period. Annual medical estimated range US$24.8 billion US$39.2 2014 annual approximately US$1,200. top 3 major components costs hospital inpatient stays, prescription medicines, office-based visits. Medicare largest source payments survivors. In terms drug consumption, genitourinary tract agents (57.0%) antineoplastics (18.6%) main therapeutic drugs. High positively (p=0.005), having private health insurance (p=0.016), more comorbidities, not currently smoking (p=0.001), patient self-perception fair/poor status (p<0.001).From 2019, national real-world data revealed that States continued increase, which partly related characteristics.